Non dilutive funding available from certain FDA industries as well as on top of the US defence force. It’s also why they have started preparations already for IND application because once phase 1a is complete and each cohort announced every 4 weeks this gives them to huge amounts of non dilutive funding outside the US defence force.
Watch the latest webinar from the 25th of November and CEO explains the importance of Walter Reed results and first human trials to gaining access to this huge grants. This time they won’t be raising, this will be rerating
NYR Price at posting:
10.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)